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ABSTRACT
We have designed phase 1/11 human
melanoma gene therapy clinical protocol. The aim
of the study was to actively immunize HLA-A1
and/or HLA-A2-positive patients with melanoma
with an admixture of irradiated autologous tumor
cells and allogeneic melanoma cells genetically
engineered to secrete IL-6 and sIL-6R in order to
elicit or enhance specific and nonspecific anti-
melanoma immune responses to autologous
tumor cells to eradicate distant melanoma lesions.
Irradiation of autologous and allogeneic tumor
cells is a key step in preparation of cellular vaccine
because of two major reasons, (i) it inhibits cell
proliferation which is crucial in the case of
autologous cells which may form a tumor; (ii) it
increases melanoma vaccine immunogenicity.
The aim of the study was to estimate the optimal
dose of ionizing radiation which will provide
sterilization of both autologous and allogeneic
melanoma cells and will ensure cytokine
secretion.
Human melanoma cells (Mich-1) were
transduced with IL-6 and sIL-6R cDNA using
double copy bicistronic retroviral vector. Parental
and transduced cells were seeded at in six-well
tissue culture plates and were irradiated with 10,
50, 100 and 200 Gy. Secretion of both
recombinant proteins into culture was analyzed
before and 24, 48, 72, 96 hand 6, 7, 10 and 12
days following irradiation. At the same time
adherent cells were enumerated, evaluated for
viability and proliferation. At 24, 48, 72 and 96 h
postirradiation specific IL-6 and sIL-6R mRNA
levels were analyzed.
Irradiation of gene modified cells inhibited
their proliferation in the dose dependant manner.
Dose of 50 Gy sufficiently affected cell
proliferation, however, for safety reasons we
decided to use the dose of 100 Gy for vaccine
preparation. Irradiation did not inhibit secretion of
IL-6 and sIL-6R. In contrary, on a per cell basis it
significantly increased their secretion which lasted
12 days postirradiation. Interestingly, we did not
observe dose or time dependent differences in
specific mRNA cellular levels suggesting that
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increased secretion of both proteins is regulated
not on the transcriptional but rather on the
posttranscriptional level. Taking all these facts into
account we concluded that irradiation of tumor
cells may provide an effective and safe approach
for gene-modified vaccine preparation.
INTRODUCTION
Recent developments of gene transfer
technology and better understanding of
immunological mechanisms related to melanoma
growth resulted in an renewed interest in the use
of melanoma cellular vaccines - the next
generation genetically modified vaccines
(Dalgleish, 1995; Bystryn et ai, 1993). The general
principle of this approach is to locally enhance
melanoma antigens presentation or/and to provide
costimulatory signal to the immune system for the
activation of specific anti-tumor immune response
(Blankenstein, 1994; Tepper and Mulle, 1994).
One version of this strategy is to insert cytokine
genes into autologous or allogeneic tumor cells, or
other carrier cells such as fibroblasts in order to
deliver cytokines in high concentration locally to
the tumor while keeping systemic concentrations
low (Blankenstein, 1994; Tepper and Mulle,
1994)..
IL-6, multifunctional cytokine, exerts its
activity via a receptor complex composed of two
subunits, a (gp80) IL-6 binding glycoprotein, and B
(130gp) signal transducing protein (Mackiewicz et
ai, 1995). Soluble form of a subunit of the IL-6
receptor (sIL-6R) acts agonistically with IL-6 by
enhancing its activity both in vitro and in vivo
(Mackiewicz et ai, 1992; Mackiewicz et ai, 1995).
Moreover IL-6/sIL-6Rcomplex displays broader
range of biological activities than IL-6 alone by
activating cells which possess gp130 but lack
gp80 (Mackiewicz et ai, 1992). In our pre-clinical
studies introduction of IL-6 and sIL-6R genes into
low immunogenic murine melanoma cells (line B-
78-H1) caused inhibition of tumor growth, ability to
metastasize, and stimulated potent, specific and
long lasting anti-melanoma immunity (Mackiewicz
et ai, 1995; Mackiewicz et ai, 1995). Anti-
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melanoma activity of IL-6/sIL-6 complex was
significantly higher than lL-6 alone. Analysis of
tumor infiltrating cells have demonstrated that IL-
6/sIL-6R secreting melanoma cells attracted
CD8+ T cells, NK cells but not CD4+ T cells or
dendritic cells (unpublished results).
On the basis of obtained results we have
designed phase 1/11 human melanoma gene
therapy clinical protocol (Mackiewicz et ai, 1995).
The aim of the study was to actively immunize
HLA-A1 and/or HLA-A2-positive patients with
melanoma with an admixture of irradiated
autologous tumor cells and allogeneic melanoma
cells genetically engineered to secrete IL-6 and
sIL-6R in order to elicit or enhance specific and
nonspecific anti-melanoma immune responses to
autologous tumor cells to eradicate distant
melanoma lesions.
Irradiation of autologous and allogeneic
tumor cells is a key step in preparation of cellular
vaccine because of two major reasons, (I) it
inhibits cell proliferation which is crucial in the
case of autologous cells which mayform a tumor;
(ii) it increases melanoma vaccine
immunogenicity. Melanoma is known to be
radioresistant. In addition, significant differences in
radiosensitivity of melanoma cells isolated from
different patients were reported. Consequently the
optimal dose of ionizing radiation providing
sterilization of both autologous and allogeneic
melanoma cells as well as ensuring cytokine
secretion needs to be estimated. Moreover, the
molecular mechanisms induced by irradiation and
governing altered secretion of recombinant
proteins need to be elucidated.
MATERIAL AND METHODS
Construction of retroviral vectors caring IL-6
and sIL-6R cDNA
Construction of double copy dicistronic
(DCCMV) vectors was based on original MSCV
vector as described in detail (Wiznerowicz et ai,
1997). Briefly, into MSCV's U3 region of 3' LTR
downstream of Nhel site artificial polylinker
containing Clal, Nrul, Sacll and Mlul unique
restriction sites was cloned. Moreover pgk-Neo
cassette was removed from the transcription
region of the vector. Next, Pstl fragment
containing human CMV-IE promotor/enhancer
was blunt ligated into Nrul site and then
Sall-BamHI fragment containing IRES-Neo
cassette was blunt ligated into filled Mlul site.
Then human IL-6 or human sIL-6RcDNAs cut out
from pEXIL-6 and pEXSIRI expression vectors
(obtained from Dr. S. Rose-John, Mainz,
Germany) were inserted into Sal I site of DCCMV.
105
Transduction of human melanoma cells
PA-317 amphotropic packaging cells
were electroporated (300V/100ms) with 5 mg of
Scal linearized plasmid DNA (DCCMV-IL-6 and
DCCMV-sIL-6R) and selected with geneticin (500
mg/ml). After 3 weeks of selection the infectious
medium containing recombinant retroviruses was
obtained by incubation for 16 h of subconfluent
(70-80%) corresponding PA~317 cells. The media
were collected, complemented with polybrene and
added for 4 hrs to human melanoma cell line
(Mich-1). Then the cells were selected in
geneticine for 3 weeks.
Maintenance and irradiation of melanoma cells
Parental and transduced cells were
seeded at identical concentrations (34 x 103/well)
in six-well tissue culture plates (Corning). After 24
h wells were filled up with the medium and plates
irradiated at room temperature with 10, 50, 100
and 200 Gy and energy 6MV using linear
accelerator Saturn 43F (General Electric).
Irradiated cells were cultured in DMEM
supplemented with 5% FCS at 37°C in 5%
COi95%· air incubator.
Determination of IL-6 and s1L-6 secretion by
melanoma cells
Secretion of IL-6 and sIL-6R by
melanoma cells into culture was analyzed before
and 24, 48, 72, 96 hand 6, 7, 10 and 12 days
following irradiation. Twenty four hours before
each time point of analysis medium was changed.
Then the medium was collected and IL-6 and slL-
6R concentration was determined using ELISA
kits (Genzyme and R&D, respectively).
Analysis of cell viability and proliferation
At each time point adherent cells were
washed, trypsinized, enumerated and evaluated
for viability using trypan blue exclusion. In parallel
wells proliferation of irradiated cells was analyzed
using MIT assay (Waserman and Twentyman,
1988). Briefly, to each well 200 ml of MIT solution
(4 mg/ml) was added and incubated for 4h at
37°C. Then to each well 1 ml of DMSO was added
and incubated for 1h at room temperature.
Following incubation absorbance was measured
at 570/630 nm wave length. In three experiments
parallel to MIT assay cell proliferation was
assessed by 3H-thymidine incorporation assay ().
Analysis of IL-6 and s1L·6 mRNA
RNA from melanoma cells transduced
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with IL-6 and sIL-6R was isolated 24, 48, 72 and
96 h following irradiation using Chomczynski and
Sacchi method (Chomczynski and Sacchi, 1987).
Specific IL-6 and sIL-6R mRNA levels were
analyzed by Northern blot using 440 bp Taql-Banll
fragment of IL-6 eDNA and Pst! 600 bp fragment
of sIL-6R eDNA, labeled by random priming. As a
control B-actin mRNA was analyzed.
RESULTS
Construction of DCCMV-IL-G and
DCCMV-sIL-6R vectors
irradiation. while dose of 1 Gy at about 90h (Fig.
2). Six days after irradiation there were no
differences between doses of 5, 10 and 20 Gy.
Enumeration of adherent cells at different
time points demonstrated progressive increase in
cell number of unirradiated cells (Fig. 3A).
Irradiation caused dose dependent reduction of
adherent cells. Until 48h following irradiation an
increase of cell number was still observed.
However, after that time progressive decrease of
adherent cells was seen (Fig. 3B-E). Trypan blue
exclusion analysis demonstrated 93-98% viable
cells.
Principles of construction of DCCMV-IL-6
and DCCMV-sIL-6R vectors are shown in Fig. 1.
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Fig. 1.
Structure and principle of double copy bicistronic vector
(DCCMV-IL-6 or sIL-6R). Bicistronic gene driven by CMV-IE
promoter was inserted into U3 region of 3'LTR of MSCV.
Reverse transcription of DCCMV-IL-6 or sIL-6R RNA in target
cells results in the CMV-IE-IL-6 or sIL-6R-IRES-Neo
transcriptional unit in the U3 region of 3'LTR being transferred to
the 5'LTR such that the DCCMV-IL-6 or sIL-6R provirus harbors
two copies. one copy in each LTR. Arrows represent transcripts.
Effect of irradiation on cell proliferation and
viability
Both cell proliferation assays, the MTT
and 3H-thymidine incorporation demonstrated
similar results. Accordingly for further studies MTT
assay was employed. Results of proliferation of
irradiated cells were expressed as percentage of
unirradiated corresponding cells. Irradiation
caused dose dependent inhibition of melanoma
cells proliferation. There were no differences
between non transduced and IL-6 or sIL-6R gene
transduced Mich-1 cells. Doses of 5, 10 and 20
Gy inhibited proliferation by 50% at 48h following
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Fig. 2.
Inhibition of melanoma cells proliferation by Irradiation with
various doses as indicated.
Production of IL-G and sIL-6R by melanoma
cells following irradiation
Twenty four hours after seeding Mich-1
cells secreted approximately 300 and 100
ng/106cells/24h of IL-6 and sIL-6R respectively.
During maintenance in culture Mich-1 cells
demonstrated similar pattern of secretion of both
proteins. Amount of IL-6 and sIL-6R accumulated
in the medium of unirradiated cells kept increasing
until the 7th day of culture and then despite the
increase of cell number progressively declined
(Fig. 3). Cells irradiated with various doses
displayed similar pattern of IL-6 and sIL-6R
secretion which reached maximum at 96h
following irradiation. Amount of both proteins
secreted was dependent on dose of irradiation.
Calculation of secretion on a per cell basis
demonstrated significant increase of secretion of
both proteins by irradiated cultures.
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Northem blot analysis of IL-6 and sIL-6R
specific mRNAs isolated from adherent cells
demonstrated no significant differences between
unirradiated and irradiated cells at 24, 48, 72 and
96 h postirradiation. Moreover, no differences





sIL-6R in the culture medium (bars) and adherent cells number at
different Iime points poslirradialion. A - unirradiated cells; B - cells
irradiated with 10 Gy; C - with 50 Gy; D - with 100 Gy and E - with
200 Gy. Number ot cells expressed in thousands. Note different
scales on each sIL-6R concentralion and celi number axis.
One of components of our genetic cellular
vaccine is a human melanoma celi line modified to
secrete recombinant IL-6 and sIL-6R. cDNAs
encoding both factors were transduced into
melanoma cells using recombinant retrovirus.
Retroviral vector used in the system was
especially designed for these studies. It combines
two strategies double copy vector and dicistronic
gene concept. Double copy strategy provides high
number of copies of transduced gene while
dicistronic gene provides simultaneous expression
of two transduced genes within one celi ensuring
expression of therapeutic gene in all selected
cells. Moreover, such a construct allows
application of various exogenous promoters
depending on the target celi requirement. In our
DCCMV vector we have employed very strong
promoter with enhancer from CMV virus which
provided high expression of both therapeutic
genes. Secretion of IL-6 or sIL-6R did not affect
melanoma cells growth in vitro (proliferation) even
when both components were present.
Irradiation of gene modified cells inhibited
their proliferation in the dose dependant manner.
Dose of 50 Gy sufficiently affected celi proliferation
and from theoretical point of view would be
appropriate for further application. However, for
safety reasons we decided to use the dose of 100
Gy in the vaccine preparation. Similar results were
obtained by others who found the dose of 40 Gy
was sufficient for irradiation of gene modified
autologous melanoma cells derived from various
patients (Abdel-Wahab et al, 1996). Similarly they
choose to use the dose of 100 Gy for the same
reason. Others have employed 100 Gy as a
standard dose to irradiate interferon gamma (INF)
and IL-2 transduced human melanoma celi lines
O, They also found significant differences in
sensitivity of particular celi line to irradiation,
however, at day 14 postirradiation they saw
between 10-30% of viable cells compared to day 3
postirradiation.
Irradiation did not inhibit secretion of both
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basis it significantly increased their secretion
which lasted 12 days postirradiation. Similar
observations were made by others in relation to
other recombinant proteins (Abdel-Wahab et ai,
1996). Taking the reduction of cell number and the
level of IL-6 and sIL-6R secretion into account we
may conclude that irradiation of tumor cells may
provide an effective and safe approach of gene-
modified vaccine preparation. Interestingly, we did
not observe dose or time dependent differences in
specific mRNA cellular levels suggesting that
increased secretion of both proteins is regulated
not on the transcriptional but rather on the
posttranscriptional level. Our results are in a
disagreement with studies of Abdel-Wahab et al.
(Abdel-Wahab et ai, 1996) who demonstrated by
RT-PCR analysis differences in IL-2 mRNA levels·
between 7 and 14 days postirradiation. In our
studies we have analyzed mRNA levels until 96h
postirradiation using Northern blot assay. This
method is more reliable than RT-PCR, however;
requires larger amounts of RNA for analysis.
Accordingly, quantities of RNA obtained from cells
on day 7 and 12 were not sufficient to perform the
Northern blot. However, observed differences may
.be due to the various promoters used in the
retroviral vectors. Abdel.,.Wahab et al. (Abdel-
Wahab et ai, 1996) used Moloney leukemia virus
LTR while in our vector we employed CMV
promoter. This is supported by their result showing
no changes in r..-actin mRNA concentration what
may indicate involvement of various nuclear
transcription factors. In addition, Hauser et al.
(Hauser et ai, 1993) demonstrated increased
expression of surface MHC class I (H-2Db)
antigens on 816 murine melanoma cells following
irradiation what was accompanied by increased
specific mRNA levels. Similarly, they did not
observe changes in (l,-actin mRNA and c-myc
mRNA, a well known modulator of MHC class I
transcription (Vesteeg et ai, 1988).
In our studies we did not analyze
expression of MHC surface molecules. As
mentioned above (Hauser et ai, 1993) and
i:1emonsll"~neb 'oy 6'mers •(Aoae(-Vvanab at ai,
1WbT iii Muman melanoma cell lines irradiation
leads to increased expression of these surface
antigens enhancing the immunogenicity of cancer
cells. This phenomenon demonstrates another
benefit of irradiation in the process of cellular
vaccine preparation.
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